ciprofloxacin has been researched along with Airflow Obstruction, Chronic in 21 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) is in development as long-term intermittent therapy to reduce the frequency of acute exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients with respiratory bacterial pathogens." | 9.24 | Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers. ( Kappeler, D; Kietzig, C; Nagelschmitz, J; Sommerer, K; Stass, H; Weimann, B, 2017) |
| "Ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) is in development as long-term intermittent therapy to reduce the frequency of acute exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients with respiratory bacterial pathogens." | 5.24 | Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers. ( Kappeler, D; Kietzig, C; Nagelschmitz, J; Sommerer, K; Stass, H; Weimann, B, 2017) |
| "A total of 150 patients with COPD, non-CF bronchiectasis or asthma, and P." | 3.11 | Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma? ( Alispahic, IA; Andreassen, HF; Armbruster, K; Bangsborg, J; Bodtger, U; Browatzki, A; Christensen, CW; Coia, JE; Datcu, R; Eklöf, J; Ellingsgaard, T; Fenlev, CS; Ghathian, KSA; Gundersen, L; Harboe, ZB; Heidemann, M; Janner, J; Jensen, JUS; Jensen, TT; Johansson, SL; Johnsen, S; Kjærgaard, JL; Lapperre, TS; Linde, H; Moberg, M; Nielsen, TL; Overgaard, RH; Pedersen, L; Rosenvinge, FS; Saeed, MI; Seersholm, N; Sivapalan, P; Sørensen, VM; Titlestad, I; Ulrik, CS; Vijdea, R; Weinreich, UM; Wilcke, T; Østergaard, C, 2022) |
| "Upper respiratory tract infections (URTI) frequently cause exacerbations of chronic-obstructive pulmonary disease (COPD)." | 2.76 | Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial. ( Isbaniah, F; Setiawati, A; Totzke, U; Verbruggen, MA; Wiyono, WH; Yunus, F, 2011) |
| "In patients with acute exacerbation of COPD requiring mechanical ventilation, efficacy of trimethoprim-sulfamethoxazole was not inferior to ciprofloxacin." | 2.75 | Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. ( Abroug, F; Besbes, L; Boukef, R; Daami, M; Elatrous, S; Marghli, S; Nciri, N; Nouira, S, 2010) |
| "influenzae in individuals with COPD." | 1.43 | Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. ( Gent, JF; Holden, PN; Kong, Y; Murphy, TF; Pettigrew, MM; Sethi, S; Tsuji, BT, 2016) |
| "Treatment with ciprofloxacin is associated with a significant increase in the risk of theophylline toxicity." | 1.37 | Ciprofloxacin-induced theophylline toxicity: a population-based study. ( Antoniou, T; Gomes, T; Juurlink, DN; Mamdani, MM, 2011) |
| "We evaluated the pharmacokinetic profile of ciprofloxacin and its penetration into bronchial secretions of critically ill patients with chronic obstructive pulmonary disease (COPD)." | 1.37 | Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. ( Argyropoulou-Pataka, P; Chatzika, K; Kioumis, I; Kontou, P; Pitsiou, G; Stanopoulos, I, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Eklöf, J | 1 |
| Alispahic, IA | 1 |
| Sivapalan, P | 1 |
| Wilcke, T | 1 |
| Seersholm, N | 1 |
| Armbruster, K | 1 |
| Kjærgaard, JL | 1 |
| Saeed, MI | 1 |
| Nielsen, TL | 1 |
| Browatzki, A | 1 |
| Overgaard, RH | 1 |
| Fenlev, CS | 1 |
| Harboe, ZB | 1 |
| Andreassen, HF | 1 |
| Lapperre, TS | 1 |
| Pedersen, L | 1 |
| Johnsen, S | 1 |
| Ulrik, CS | 1 |
| Janner, J | 1 |
| Moberg, M | 1 |
| Heidemann, M | 1 |
| Weinreich, UM | 1 |
| Vijdea, R | 1 |
| Linde, H | 1 |
| Titlestad, I | 1 |
| Johansson, SL | 1 |
| Rosenvinge, FS | 1 |
| Østergaard, C | 1 |
| Ghathian, KSA | 1 |
| Gundersen, L | 1 |
| Christensen, CW | 1 |
| Bangsborg, J | 1 |
| Jensen, TT | 1 |
| Sørensen, VM | 1 |
| Ellingsgaard, T | 1 |
| Datcu, R | 1 |
| Coia, JE | 1 |
| Bodtger, U | 1 |
| Jensen, JUS | 1 |
| Sethi, S | 2 |
| Aaron, SD | 1 |
| Begbey, A | 1 |
| Guppy, JH | 1 |
| Mohan, C | 1 |
| Webster, S | 1 |
| Ben-Chetrit, E | 1 |
| Rothstein, N | 1 |
| Munter, G | 1 |
| Lee, SH | 1 |
| Teo, J | 1 |
| Heng, D | 1 |
| Zhao, Y | 1 |
| Ng, WK | 1 |
| Chan, HK | 2 |
| Tan, RB | 1 |
| Puig, C | 1 |
| Tirado-Vélez, JM | 1 |
| Calatayud, L | 1 |
| Tubau, F | 1 |
| Garmendia, J | 1 |
| Ardanuy, C | 1 |
| Marti, S | 1 |
| de la Campa, AG | 1 |
| Liñares, J | 1 |
| Ercibengoa Arana, M | 1 |
| Marimón Ortiz de Zarate, JM | 1 |
| Pettigrew, MM | 1 |
| Tsuji, BT | 1 |
| Gent, JF | 1 |
| Kong, Y | 1 |
| Holden, PN | 1 |
| Murphy, TF | 1 |
| Stass, H | 1 |
| Nagelschmitz, J | 1 |
| Kappeler, D | 1 |
| Sommerer, K | 1 |
| Kietzig, C | 1 |
| Weimann, B | 1 |
| Adi, H | 1 |
| Young, PM | 1 |
| Agus, H | 1 |
| Traini, D | 1 |
| Nouira, S | 1 |
| Marghli, S | 1 |
| Besbes, L | 1 |
| Boukef, R | 1 |
| Daami, M | 1 |
| Nciri, N | 1 |
| Elatrous, S | 1 |
| Abroug, F | 1 |
| Fantin, B | 1 |
| Isbaniah, F | 1 |
| Wiyono, WH | 1 |
| Yunus, F | 1 |
| Setiawati, A | 1 |
| Totzke, U | 1 |
| Verbruggen, MA | 1 |
| Antoniou, T | 1 |
| Gomes, T | 1 |
| Mamdani, MM | 1 |
| Juurlink, DN | 1 |
| Hayes, D | 1 |
| Diaz-Guzman, E | 1 |
| Hoopes, CW | 1 |
| Kontou, P | 1 |
| Chatzika, K | 1 |
| Pitsiou, G | 1 |
| Stanopoulos, I | 1 |
| Argyropoulou-Pataka, P | 1 |
| Kioumis, I | 1 |
| Serisier, DJ | 1 |
| Pletz, MW | 1 |
| McGee, L | 1 |
| Burkhardt, O | 1 |
| Lode, H | 1 |
| Klugman, KP | 1 |
| Shmelev, EI | 1 |
| Brückner, O | 1 |
| Trautmann, M | 1 |
| Dareau, S | 1 |
| Eledjam, JJ | 1 |
| Gros, T | 1 |
| Delire, V | 1 |
| Causse, L | 1 |
| Javitary, W | 1 |
| Bassoul, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Targeted AntiBiotics for Chronic Pulmonary Disease: Can Targeted Antibiotic Therapy Improve the Prognosis of Pseudomonas Aeruginosa Infected Patients With Chronic Pulmonary Obstructive Disease, Non-cystic Fibrosis Bronchiectasis and Asthma? A Multicenter,[NCT03262142] | Phase 4 | 51 participants (Actual) | Interventional | 2018-01-10 | Terminated (stopped due to Slow recruitment) | ||
| Antibiotic Comparison Exacerbation COPD[NCT00791505] | Phase 3 | 170 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ciprofloxacin and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
Topics: Administration, Inhalation; Animals; Anti-Bacterial Agents; Bronchiectasis; Ciprofloxacin; Clinical | 2012 |
[Respiratory fluoroquinolones in the treatment of exacerbations of chronic obstructive lung disease].
Topics: Administration, Oral; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Bacteria; Cefepime; Cep | 2004 |
4 trials available for ciprofloxacin and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Targeted AntiBiotics for Chronic pulmonary diseases (TARGET ABC): can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa-infected patients with chronic pulmonary obstructive disease, non-cystic fibrosis bronchiectasis, and asthma?
Topics: Anti-Bacterial Agents; Asthma; beta-Lactams; Bronchiectasis; Ciprofloxacin; Fibrosis; Humans; Predni | 2022 |
Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers.
Topics: Administration, Inhalation; Adult; Aged; Anti-Bacterial Agents; Biological Availability; Bronchiecta | 2017 |
Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Female; H | 2010 |
Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: results from a randomized controlled trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ascorbic Acid; Ciprofloxacin; | 2011 |
15 other studies available for ciprofloxacin and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Antibiotic Retreatment for Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Humans; Pulmonary Disease, Chronic Obstru | 2020 |
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Cl | 2020 |
Ciprofloxacin-induced psychosis.
Topics: Bronchiectasis; Ciprofloxacin; Humans; Lung; Male; Middle Aged; Psychoses, Substance-Induced; Pulmon | 2013 |
Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bacterial Infections; Beclomethasone; Ciprofloxac | 2014 |
Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; Ciproflo | 2015 |
First report of Nocardia fusca isolated in humans.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Ciprofloxacin; Diagnosis, Differential; Humans; Male; No | 2015 |
Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Macrol | 2016 |
Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Anti-Infective Agents; Chemistry, Pharmaceutical; Ciprofloxacin; Cystic | 2010 |
Reduced antibiotic pressure for the treatment of acute exacerbation of chronic obstructive pulmonary disease: back to the future.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Pulmonary Disease, Chronic Obstructive; Randomized Con | 2010 |
Ciprofloxacin-induced theophylline toxicity: a population-based study.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Ciprofloxacin; Drug Interactions; Female; Humans; Mal | 2011 |
Rhodococcus equi infection after lung transplantation.
Topics: Actinomycetales Infections; Anti-Bacterial Agents; Ciprofloxacin; Humans; Immunity, Cellular; Immuno | 2011 |
Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease.
Topics: Anti-Infective Agents; Bronchi; Chromatography, High Pressure Liquid; Ciprofloxacin; Critical Illnes | 2011 |
Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Therapy, Combination; F | 2005 |
Efficacy and safety in the oral treatment of purulent chest disease and pneumonia with cefixime, ofloxacin, and ciprofloxacin.
Topics: Administration, Oral; Anti-Bacterial Agents; Bronchitis; Cefixime; Ciprofloxacin; Clinical Trials as | 1989 |
[Postoperative pneumonia: nosocomial, predictable, iatrogenic, preventable or not?].
Topics: Alcoholism; Amoxicillin-Potassium Clavulanate Combination; Antibiotic Prophylaxis; Carcinoma, Squamo | 2006 |